Investment Rating - The report maintains a "Strong Buy" rating for 加科思-B (01167.HK) with a target price of HKD 11.65, compared to the current price of HKD 6.99 [2][4]. Core Insights - 加科思 has released its 2025 annual performance report, showcasing promising efficacy data for its pan-KRAS inhibitor JAB-23E73, which is considered to have best-in-class potential [2]. - The company expects to turn profitable in 2026, with significant revenue growth anticipated from its innovative drug pipeline, particularly the pan-KRAS inhibitor [8]. - The report highlights the company's strong cash reserves, projected to exceed HKD 2 billion by the end of Q1 2026, which will support its clinical trials and operational activities [8]. Financial Summary - Total revenue for 2025 is reported at HKD 54 million, with a projected increase to HKD 670 million in 2026, reflecting a year-on-year growth rate of 1,152.2% [4]. - The net profit attributable to shareholders is expected to be HKD 417 million in 2026, a significant turnaround from a loss of HKD 146 million in 2025 [4]. - Earnings per share (EPS) is projected to improve from -0.18 in 2025 to 0.53 in 2026, indicating a positive shift in profitability [4]. Clinical Development and Market Position - The pan-KRAS inhibitor JAB-23E73 has shown an overall response rate (ORR) of 38.5% in a domestic pancreatic cancer subgroup, outperforming competitors in the same class [8]. - The company is advancing its next-generation antibody-drug conjugate (ADC) platforms, which are expected to expand its treatment options and market reach [8]. - 加科思's KRAS G12C inhibitor, 戈来雷塞, has already contributed revenue and is expanding its indications, with sales expected to grow following its inclusion in medical insurance [8].

1. Report Industry Investment Rating There is no information provided in the content about the report's industry investment rating. 2. Core Viewpoints of the Report - The macro - policy in 2026 emphasizes expanding domestic demand, with a focus on boosting consumption and investment, optimizing traditional industries, and fostering emerging and future industries. Fiscal and monetary policies are coordinated to support economic growth, while financial supervision and real - estate policies aim to maintain stability and prevent risks. The international trade situation is affected by the US tariff policy changes [1][2][3]. 3. Summary According to the Directory 3.1 Macro - tone: Expand Domestic Demand First, Support Investment and Optimize Consumption - **Consumption**: The government emphasizes building a strong domestic market, implementing a special consumption - boosting action. It allocates 250 billion yuan in ultra - long - term special treasury bonds for consumer goods trade - in and 100 billion yuan in fiscal - financial cooperation policies to promote domestic demand, with greater intensity than last year [1][11]. - **Investment**: The government aims to fully tap and release effective investment potential, stimulate private investment, and increase the scale of new policy - based financial instruments to 800 billion yuan to drive more social capital into investment. The investment in "Six Networks" and key areas in 2026 will exceed 7 trillion yuan [12]. - **Industry**: Traditional industries are optimized and upgraded with 200 billion yuan in ultra - long - term special treasury bonds for large - scale equipment renewal. Emerging and future industries such as integrated circuits and quantum technology are to be cultivated and expanded, with the related output value of six new industries expected to double or more by 2030 [13]. - **Technological Innovation**: The government attaches more importance to technological innovation, and more supporting policies may be introduced in the future [13]. - **Reform**: The focus of reform is adjusted, with the construction of a unified national market and fiscal - financial system reform given higher priority [14]. 3.2 Fiscal Policy: Ultra - long Bonds and Quasi - fiscal Tools Actively Contribute, and the Expenditure Structure is More Optimized - **Policy Tone**: The active fiscal policy continues, with fiscal expenditure maintaining scale and optimizing the structure. The deficit rate is set at about 4%, and the deficit scale is 5.89 trillion yuan, an increase of 230 billion yuan from last year [17]. - **Special Treasury Bonds**: The ultra - long - term special treasury bonds remain at 1.3 trillion yuan, with 800 billion for "Two Important" projects and 500 billion for "Two New" policies. The special treasury bonds for supplementing the capital of large - scale commercial banks are reduced to 300 billion yuan [18]. - **New Special Bonds**: The scale of new local government special bonds remains at 4.4 trillion yuan, and the report proposes to improve the management of the negative list of special bond projects and the self - review and self - issuance pilot [19]. - **New Policy - based Financial Tools**: The scale increases to 80 billion yuan, which can effectively supplement the capital of major projects, and the capital injection may be earlier than last year [20]. - **Fiscal - Financial Cooperation to Promote Domestic Demand**: The scale is 10 billion yuan, focusing on supporting private investment and household consumption [23]. - **Debt Resolution**: The risk resolution of local government financing platform debts has achieved important phased results. By the end of 2025, compared with the beginning of 2023, the number of financing platforms and the debt scale have both decreased by more than 70% [21]. 3.3 Monetary Policy: Cost Reduction Focuses on "Intermediate Fees", and Overall Easing Still Needs to Wait - **Policy Tone**: The "moderately loose" monetary policy continues, and the probability of short - term reserve requirement ratio cuts and interest rate cuts is limited. The central bank focuses on reducing intermediate fees in credit financing [24]. - **Financial Risk**: The 10 - year treasury bond yield stabilizes around 1.8%, and the central bank is studying a liquidity support mechanism for non - bank institutions in specific situations and supports the Central Huijin Company to play a role similar to a "stabilization fund" [25]. - **Exchange Rate**: The central bank lowers the foreign exchange risk reserve ratio for forward foreign exchange sales, indicating that the RMB exchange rate against the US dollar is in the median range in recent years, and the central bank has no intention to guide the RMB to depreciate [26]. - **Monetary Policy Report**: It proposes to view the total liquidity from the combined perspective of asset management products and bank deposits [27]. - **Central Bank Bond Purchases**: The scale is reduced to 50 billion yuan, indicating a relatively cautious attitude [28]. 3.4 Financial Supervision: Coordinate Risk Prevention and Development, and Firmly Hold the Safety Bottom Line - **Policy Tone**: Continue to emphasize the prevention of risks in key areas, and details are more focused on risk resolution [31]. - **Capital Market Reform**: Deepen the reform of the Growth Enterprise Market and optimize the refinancing mechanism to better serve technological innovation and the development of new - quality productivity [32]. - **Financial Risk**: The number of high - risk small and medium - sized financial institutions has been significantly reduced, and capital replenishment methods are expected to be gradually expanded [33]. - **Inter - bank Current Deposits**: The self - regulatory management of inter - bank current deposits has become stricter, with the scope expanded and a quarterly ratio limit introduced [34]. 3.5 Real - estate Policy: Focus on Stabilizing the Market, Centering on "Controlling Increment, Reducing Inventory, and Optimizing Supply" - **Policy Tone**: The regulatory tone in 2026 changes from "promoting the market to stop falling and stabilize" to "focusing on stabilizing the market", with a focus on "controlling increment, reducing inventory, and optimizing supply", and a new proposal to deepen the reform of the housing provident fund system [37]. - **Local Policies**: Shanghai issues the "Shanghai Seven - Point Plan", and Jiangsu, Chongqing, and Shenzhen optimize real - estate market policies [38]. - **Land Supply**: The total amount of construction land is controlled during the planning period, and the importance of revitalizing the stock is further enhanced [39]. 3.6 Sino - US Tariffs: The Supreme Court Rules the Counter - tariff Policy Invalid, and Alternative Measures are Successively Introduced - **Counter - tariff Policy**: The US Supreme Court rules that the counter - tariff policy implemented by the Trump administration lacks clear legal authorization [42]. - **Alternative Measures**: Trump announces an additional 10% import tariff on global goods, which is later raised to 15%. The US also announces a new round of "301 investigations" on 16 major trading partners, and China and the US are to hold the 6th round of economic and trade consultations [42][43].

Investment Rating - The report maintains a "Strong Buy" rating for the company with a target price of 515.63 CNY [2][8]. Core Insights - The company's performance in 2025 significantly exceeded expectations, with total revenue reaching 423.7 billion CNY, a year-on-year increase of 17.0%, and a net profit attributable to shareholders of 72.2 billion CNY, up 42.3% year-on-year [10][37]. - The company is expected to experience high growth in production capacity in 2026, driven by strong demand and an increase in orders, as evidenced by a 77% increase in contract liabilities in Q4 2025 [27][37]. - The company achieved a global market share of 39.2% in electric vehicle battery installations, marking a 1.2 percentage point increase year-on-year, and continues to lead in the high-end market segment [37][40]. Financial Performance Summary - **Revenue and Profitability**: In 2025, the company reported total revenue of 423.7 billion CNY, with a net profit of 72.2 billion CNY, reflecting a 42.3% increase year-on-year. The fourth quarter alone saw revenue of 1,406.3 billion CNY, a 36.6% increase from the previous quarter [10][19]. - **Sales Volume**: The total battery sales volume reached 661 GWh in 2025, a 39.2% increase year-on-year, with a significant contribution from both power and energy storage batteries [10][37]. - **Margins**: The gross margins for power batteries, energy storage, materials, and minerals were 23.8%, 26.7%, 27.3%, and 11.3% respectively, with notable improvements in materials and minerals due to price increases [17][19]. Capacity and Investment - **Capital Expenditure**: The company has resumed capital expenditure growth, with Q4 2025 capital spending reaching 12.3 billion CNY, indicating a return to an expansion phase [21][27]. - **Production Capacity**: As of the end of 2025, the company had 321 GWh of capacity under construction, with plans for further expansion in 2026 [21][27]. Cash Flow and Financial Health - **Cash Flow**: The company reported a strong operating cash flow of 1,332 billion CNY in 2025, a 37.4% increase year-on-year, with cash on hand increasing to 299.9 billion CNY [33][36]. - **Debt and Liabilities**: The company's contract liabilities rose significantly, indicating robust demand and a strong order backlog, with Q4 2025 contract liabilities at 49.2 billion CNY [27][29]. Market Position and Product Development - **Market Share**: The company achieved a record global market share of 39.2% in electric vehicle battery installations, outperforming the overall market growth [37][40]. - **Product Innovation**: The company continues to launch innovative products, including various battery solutions tailored for different applications, enhancing its competitive advantage [40][42].

Investment Rating - The report maintains a "Recommended" rating for the company, with a target price of HKD 13.1 for 2026 [2][8]. Core Views - The company is expected to experience a significant decline in shareholder profit, projected to drop approximately 95% to RMB 0.92 billion by December 31, 2025, compared to RMB 15.96 billion in 2024 [2][4]. - Despite short-term profit pressures, the long-term outlook remains positive due to the company's precise land acquisition strategies [2][8]. - The company has shown strong sales performance, with a projected sales amount of RMB 1,534 billion for 2025, reflecting a year-on-year decrease of 10.2% [8]. Financial Summary - Total revenue is expected to decline from RMB 158.546 billion in 2024 to RMB 143.229 billion in 2025, representing a year-on-year decrease of 9.7% [4][9]. - The net profit attributable to shareholders is forecasted to fall from RMB 1.596 billion in 2024 to RMB 0.092 billion in 2025, a decrease of 94.2% [4][9]. - The company's earnings per share (EPS) is projected to be RMB 0.04 in 2025, significantly down from RMB 0.63 in 2024 [4][9]. - The company maintains a healthy financial structure, with a debt ratio of 76.97% and a cash-to-short-term debt ratio exceeding 2.5 times [5][8]. Land Acquisition and Sales Performance - The company has demonstrated a high level of precision in land acquisition since 2022, with a net profit margin exceeding 8% for new land projects acquired during 2022-2024 [8]. - The investment intensity for land acquisition is approximately 47%, with a total land acquisition amount of RMB 719 billion in 2025 [8]. - The company is focusing on key cities such as Hangzhou, Shanghai, Suzhou, and Xi'an, which account for about 70% of its land acquisitions [8].

港股公司 证 券 研 究 报 告 绿城中国（03900.HK）2025 年盈利警告点评 推荐（维持） ❖ 根据公司未经审核综合管理账目及现有数据的初步评估，预计截至 2025 年 12 月 31 日年度，公司股东应占利润较 2024 年同期的人民币 15.96 亿元下降约 95%。 评论： [主要财务指标 Indicator_FinchinaSimpleHK] | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万元) | 158,546 | 143,229 | 129,314 | 108,330 | | 同比增速(%) | 20.7% | -9.7% | -9.7% | -16.2% | | 归母净利润(百万元) | 1,596 | 92 | 547 | 580 | | 同比增速(%) | -48.4% | -94.2% | 493.5% | 6.2% | | 每股盈利(元) | 0.63 | 0.04 | 0.22 | 0.23 | | 市盈率(倍) | 15 | 252 | 43 | 40 | | 市净 ...

Investment Rating - The report maintains a "Strong Buy" rating for the company with a target price of 515.63 CNY [2][8]. Core Insights - The company significantly exceeded expectations in 2025, achieving a revenue of 423.7 billion CNY, a year-on-year increase of 17.0%, and a net profit attributable to shareholders of 72.2 billion CNY, up 42.3% year-on-year [10][37]. - The company is expected to experience high growth in production capacity in 2026, driven by strong demand and an increase in orders [10][27]. - The company’s global market share in electric vehicle batteries reached a new high of 39.2%, with a total installed capacity of 464.7 GWh, reflecting a year-on-year growth of 36% [37][40]. Financial Performance Summary - **Revenue and Profitability**: In 2025, the company reported total revenue of 423.7 billion CNY, with a net profit of 72.2 billion CNY. The fourth quarter alone saw revenue of 140.6 billion CNY, a quarter-on-quarter increase of 36.6% [10][19]. - **Sales Volume**: The total battery sales volume reached 661 GWh, marking a 39.2% increase year-on-year, with a notable rise in both power and energy storage battery sales [10][37]. - **Margins**: The gross margins for power batteries, energy storage, materials, and minerals were 23.8%, 26.7%, 27.3%, and 11.3% respectively, with material margins improving due to price increases [17][19]. Capacity and Investment - **Capital Expenditure**: The company’s capital expenditure returned to an expansion phase in 2025, with Q4 capital spending reaching 12.3 billion CNY, indicating a commitment to increasing production capacity [21][27]. - **Construction Progress**: As of the end of 2025, the company had 321 GWh of capacity under construction, with ongoing projects expected to further enhance production capabilities in 2026 [21][27]. Cash Flow and Financial Health - **Cash Flow**: The company reported a strong operating cash flow of 133.2 billion CNY in 2025, a 37.4% increase year-on-year, with cash reserves at the end of the year reaching 299.9 billion CNY [36][37]. - **Contract Liabilities**: The company’s contract liabilities surged to 49.2 billion CNY in Q4, reflecting robust demand and a strong order backlog [27][29]. Market Position and Product Development - **Market Leadership**: The company maintained its leading position in the electric vehicle battery market, with over 60% of luxury electric vehicles in China using its batteries [37][40]. - **Innovative Products**: The company has launched several innovative products, including outdoor liquid-cooled battery cabinets and large-capacity energy storage systems, enhancing its competitive edge [40][42].

Core Insights - The current liquidity remains relatively abundant, with the CSI 1000 index outperforming the overall market since the beginning of the year, increasing by 10.1% compared to 6.9% for the Wind All A and 1.6% for the CSI 300 [2][12] - Expectations for GDP deflation index to turn positive this year, coupled with strengthened policy support for technological innovation, are likely to restore risk appetite for growth sectors [2][19] - Corporate earnings are expected to continue recovering throughout the year, with the CSI 1000 showing greater fundamental elasticity [3][12] Group 1: Earnings Recovery and Market Dynamics - The current environment of abundant liquidity has led to a preference for small-cap growth stocks, with the CSI 1000 index showing a significant increase since the beginning of the year [14] - Historical trends suggest that monetary easing may lead to a return of inflation, which could positively impact corporate earnings, with an expected growth rate of 11%-17% for non-financial net profits in the entire A-share market in 2026 [3][23] Group 2: Investment Value Analysis of CSI 1000 Index - Valuation comparison indicates that the CSI 1000 index is at a medium level among major broad-based indices, with a price-to-earnings ratio of 50.8 times, which is at the 84th percentile over the past decade [4][30] - The industry distribution shows a strong focus on technology and growth sectors, with significant weights in TMT (Technology, Media, and Telecommunications) and high-end manufacturing [5][33] - The CSI 1000 index has historically outperformed the CSI 300 and CSI 800, with a cumulative return of 115% since 2010, although it is slightly lower than the Wind All A index [6][42] Group 3: Performance and Growth Expectations - The expected net profit growth rate for the CSI 1000 in 2026 is projected to be 25%, significantly higher than the overall market's 18.9% [7][46] - Recent improvements in earnings have been noted, with the CSI 1000's net profit growth recovering from a decline of -20% in Q4 2024 to -1.8% in Q3 2025 [7][46] - The CSI 1000 index's fundamental elasticity is expected to be greater during the earnings upcycle, making it a more attractive investment option [7][46] Group 4: Example of Investment Tool - The GF CSI 1000 ETF (560010) is designed to closely track the CSI 1000 index, providing investors with a tool for exposure to small-cap companies [8][47]

Investment Rating - The report assigns a "Strong Buy" rating to the company, indicating a positive outlook on its future performance [2][10]. Core Insights - The company is positioned as a leader in the domestic pharmaceutical industry, accelerating its innovation transformation. It has developed significant products such as Lijuzhiyuan, Shenqi Fuzheng Injection, and others, with revenue growth from 1.18 billion to 11.81 billion from 2000 to 2024, reflecting a compound annual growth rate (CAGR) of over 10% [7][16]. - The company is expected to enter a low base period for its existing business after risk release in 2026, with stable growth across its chemical and traditional Chinese medicine sectors [9][38]. - The innovation business is anticipated to see accelerated growth, with a projected revenue of 4.775 billion by 2030, reflecting a CAGR of 147% from 2025 to 2030 [9][37]. - The raw materials and traditional Chinese medicine segments are expected to provide stable cash flow, with a recovery in demand for key products [9][38]. Summary by Sections Company Overview - The company has evolved into a large pharmaceutical group covering research, production, and commercialization, focusing on areas such as digestive health, reproductive health, and mental health [15][16]. - It has a strong foundation in innovation, with a diverse pipeline and a commitment to high clinical value products [27][28]. Existing Business - The existing product lines are expected to stabilize post-2026, with only specific products facing risks, while others have cleared potential issues [9][41]. - The company has maintained balanced growth in its chemical and traditional Chinese medicine businesses, avoiding reliance on any single product [38]. Innovation Business - The company is set to benefit from a peak in new product launches starting in 2025, with several innovative products expected to enter the market [28][36]. - The focus on high-barrier complex formulations and high clinical value products is expected to drive significant revenue growth [34][37]. Financial Projections - The projected net profits for 2025-2027 are 20.22 billion, 20.78 billion, and 23.78 billion respectively, with corresponding growth rates of -1.9%, +2.8%, and +14.4% [10][37]. - The current stock price corresponds to a price-to-earnings (PE) ratio of only 15 times for 2026, indicating potential undervaluation [10][37].

Investment Rating - The report assigns a "Strong Buy" rating to the company, with a target price of 55.67 CNY per share based on a comprehensive valuation of 494.35 billion CNY for the company in 2026 [2][10]. Core Insights - The company is positioned as a leading player in the domestic pharmaceutical industry, accelerating its innovation transformation. It has developed significant products such as Lijuzhiyuan, Shenqi Fuzheng Injection, and others, with a revenue growth from 1.18 billion CNY in 2000 to 11.81 billion CNY in 2024, reflecting a compound annual growth rate (CAGR) of over 10% [7][16]. - The company’s existing business is expected to enter a low base period after risk release in 2026, with stable growth across its chemical and traditional Chinese medicine segments [9][38]. - The innovation business is anticipated to see accelerated growth, with a projected revenue of 4.775 billion CNY from innovative products by 2030, reflecting a CAGR of 147% from 2025 to 2030 [8][37]. Summary by Sections Company Overview - The company has evolved into a large pharmaceutical group covering drug research, production, and commercialization, focusing on areas such as digestive health, reproductive health, and mental health [15][16]. - It has a strong foundation in innovation, having established various research platforms and a diverse product pipeline [26][27]. Existing Business - The company’s chemical and traditional Chinese medicine businesses have maintained balanced growth, with only specific products facing risks, while others have cleared potential risks [38][41]. - The company’s revenue from traditional Chinese medicine is showing signs of recovery, with key products like Shenqi Fuzheng Injection benefiting from increased demand [9][41]. Innovation Business - The company is set to launch several innovative products starting in 2026, with a strong focus on high-value therapeutic areas [28][34]. - The innovative pipeline includes products in digestive health, mental health, and reproductive health, which are expected to drive significant revenue growth [8][28]. Financial Projections - The company’s projected net profits for 2025, 2026, and 2027 are 20.22 billion CNY, 20.78 billion CNY, and 23.78 billion CNY, respectively, with growth rates of -1.9%, +2.8%, and +14.4% [10][37]. - The current stock price corresponds to a price-to-earnings (PE) ratio of 15 times for 2026, indicating a favorable valuation compared to peers [10][37].

行业研究 证 券 研 究 报 告 华创农业 3 月 USDA 农产品跟踪报告 USDA 上调全球玉米产量预测，下调全球大 推荐（维持） 豆产量预测 华创证券研究所 证券分析师：张皓月 2026-02-23 《动保行业 1 月跟踪报告：1 月多数疫苗品种批 签发均同比下降，兽药 VPI 指数连续 3 个月环比 下行》 邮箱：zhanghaoyue@hcyjs.com 执业编号：S0360524070009 证券分析师：陈鹏 电话：021-20572579 邮箱：chenpeng1@hcyjs.com 执业编号：S0360521080002 行业基本数据 | | | 占比% | | --- | --- | --- | | 股票家数(只) | 101 | 0.01 | | 总市值(亿元) | 15,149.23 | 1.17 | | 流通市值(亿元) | 11,821.37 | 1.14 | 相对指数表现 | % | 1M | 6M | 12M | | --- | --- | --- | --- | | 绝对表现 | 7.6% | 0.9% | 26.5% | | 相对表现 | 8.2% | -2.7% | 7.2 ...